Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Break Below 200 Day Moving Average – Should You Sell?

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $13.29 and traded as low as $12.58. Enanta Pharmaceuticals shares last traded at $12.96, with a volume of 748,002 shares.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ENTA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a research note on Wednesday, September 23rd. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Enanta Pharmaceuticals Trading Up 0.9%

The company has a 50-day moving average of $13.13 and a 200-day moving average of $13.29. The firm has a market capitalization of $377.46 million, a price-to-earnings ratio of -5.38 and a beta of 0.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The business had revenue of $14.36 million during the quarter, compared to analyst estimates of $16.76 million. Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%. On average, research analysts forecast that Enanta Pharmaceuticals, Inc. will post -2.36 earnings per share for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC raised its stake in Enanta Pharmaceuticals by 1.5% during the first quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock worth $47,717,000 after acquiring an additional 54,396 shares during the period. Jupiter Topco LLC acquired a new position in Enanta Pharmaceuticals in the second quarter valued at approximately $53,252,000. BlackRock Inc. bought a new position in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $47,304,000. ADAR1 Capital Management LLC bought a new position in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $19,603,000. Finally, Spruce Street Capital LP acquired a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter worth approximately $15,873,698. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and liver diseases. The company’s research and development activities have included treatments for hepatitis B virus (HBV), respiratory syncytial virus (RSV), SARS-CoV-2 and other infectious diseases.

Enanta’s most notable commercial contribution is glecaprevir, a direct-acting antiviral developed in collaboration with AbbVie and included in the Mavyret and Maviret treatment for chronic hepatitis C virus (HCV) infection.